Mylan says disagrees with FDA over generic Advair delay

NEW YORK, May 10 (Reuters) - Drugmaker Mylan Inc, which is trying to launch a generic form of GlaxoSmithKline's Advair asthma treatment, on Wednesday said it is in disagreement with the U.S. Food and Drug Administration over the standards it must meet.

by reutersCOMPANYNEWS via Endless Supplies .Biz - News